Literature DB >> 15606731

Sodium tetradecyl sulfate for sclerotherapy treatment of veins: is compounding pharmacy solution safe?

Mitchel P Goldman1.   

Abstract

OBJECTIVE: The objective was to determine the composition of three available solutions of sodium tetradecyl sulfate from compounding pharmacies in comparison to pharmaceutical-grade sodium tetradecyl sulfate, Fibrovein (STD Pharmaceuticals, Ltd.).
METHODS: Solutions of 3% sodium tetradecyl sulfate were obtained from three compounding pharmacies. An analysis of their composition was performed.
RESULTS: All samples of 3% sodium tetradecyl sulfate obtained had a different concentration of sodium tetradecyl sulfate than that stated on the bottle (range, 2.59%-3.39%). Significant concentrations of the contaminant carbitol were present in samples from all three sources (0.33%-4.18%).
CONCLUSION: The production of 3% sodium tetradecyl sulfate by these three compounding pharmacies appears to occur by simple dilution of a 27% industrial detergent solution that is not manufactured for use in humans. Physicians need to be aware that the stated concentration may not be correct and that along with sodium tetradecyl sulfate, potentially harmful contaminants may be present in the solution.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15606731     DOI: 10.1111/j.1524-4725.2004.30502.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  7 in total

Review 1.  Historical overview and review of current day treatment in the management of acute variceal haemorrhage.

Authors:  Neil Rajoriya; Dhiraj Tripathi
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 2.  Variceal Bleeding: Beyond Banding.

Authors:  Lolwa N Al-Obaid; Ahmad Najdat Bazarbashi; Marvin Ryou
Journal:  Dig Dis Sci       Date:  2022-04-04       Impact factor: 3.199

Review 3.  Description of outbreaks of health-care-associated infections related to compounding pharmacies, 2000-12.

Authors:  Catherine Staes; Jason Jacobs; Jeanmarie Mayer; Jill Allen
Journal:  Am J Health Syst Pharm       Date:  2013-08-01       Impact factor: 2.637

4.  Sclerosing therapy for orbital lymphangioma using sodium tetradecyl sulfate.

Authors:  Anuchit Poonyathalang; Pisit Preechawat; Pakorn Jiarakongmun; Sirintara Pongpech
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

Review 5.  Extemporaneous Compounding: Selective Pharmacists with Separate Skill.

Authors:  A K Mohiuddin
Journal:  Innov Pharm       Date:  2019-10-31

Review 6.  Potential risks of pharmacy compounding.

Authors:  Jennifer Gudeman; Michael Jozwiakowski; John Chollet; Michael Randell
Journal:  Drugs R D       Date:  2013-03

7.  Pharmacy compounding primer for physicians: prescriber beware.

Authors:  Sarah Sellers; Wulf H Utian
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.